



Nirman Agri Genetics Limited

3rd Floor, Samarth House, Opposite Titan World, Mahatma Nagar, Nashik, India
422005.

Contact:0253-2943101

Email: admin@nirmanagrigen.com Web: www.nirmanagrigen.com

Cin No: U01110MH2020PLC344089 GST No: 27AAHCN1021C1Z3

February 05, 2025

To,
Listing Department,
National Stock Exchange Limited.
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai-400051.

Scrip Code – NIRMAN

Sub.: Outcome of Board Meeting.

Ref.: Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir / Madam,

In reference to our communication dated January 20,2025 we write to advise your good office and our stakeholders that, the meeting of Board of Directors of the Company held on Monday , February 05,2025 to consider and approve Un-Audited Standalone Financial Results of the Company along with Limited Review Report for the Quarter and Nine Months ended on December 31, 2024.

Accordingly, please find enclosed herewith a copy of the unaudited financial results of the Company for the quarter and Nine Months ended on December 31, 2024 and Limited Review Report by the Statutory Auditor of the Company.

The Board Meeting commenced at 12.00 P.M. and concluded at 01:30 P.M. The aforesaid financial results will also be hosted on the Company's website viz. www.nirmanagrigen.com.

Kindly take the same on record and oblige.

Thanking you,

For Nirman Agri Genetics Limited.

Pranav

Kailas Bagal

Digitally signed by
Pranav Kailas Bagal

Date: 2025.02.05
13:47:43 +05'30'

Pranav Kailas Bagal
Managing Director
DIN: 08839908



REVIEW REPORT ON STANDALONE
UNAUDITED FINANCIAL RESULTS


To
The Board of Directors
Nirman Agri Genetics Limited

1. We have reviewed the Standalone Unaudited Financial Results of Nirman Agri Genetics Limited ("the company") for the quarter and nine months ended December 31, 2024 which are included in the accompanying Statement of Standalone Unaudited Financial Results for the Quarter and nine months ended December 31, 2024" (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialed by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.



3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Engagements to Review of Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
4. A review is limited primarily to inquiries of company personnel and an analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practices and policies and has not disclosed the information required) to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Devendra C. Belan & Associates
Chartered Accountants
FRN - 126495W



CA. Devendra C. Belan
Proprietor
M No. 119372
Date: - 05th February 2025
UDIN: - 25119372BMHTES5668

NIRMAN AGRI GENETICS LIMITED
(Formerly known as Nirman Agri Genetics Private Limited)
Registered Office Address - 3rd Floor, Samarth House, Opp. Titan World, Mahatma Nagar, Nashik 422005
CIN - U01110MH2020PLC344089
UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2024
Pursuant to Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015

(Rs.In Lakhs)

Particulars	Quarter Ended				Nine Months Ended		Year Ended
	31-12-2024	30-09-2024	30-06-2024	31-12-2023	31-12-2024	31-12-2023	31-03-2024
Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I Revenue From Operations	6,107.20	6209.19	5,035.39	1,889.24	17,351.77	4,287.72	6,333.72
II Other Income	-	-	-	-	-	-	-
III Total Income (I+II)	6,107.20	6,209.19	5,035.39	1,889.24	17,351.77	4,287.72	6,333.72
IV Expenses							
Cost of Materials Consumed , Cost of Production	5,276.29	5428.39	4,411.46	1473.79	15,116.14	3,312.91	4,933.60
Purchases of Stock -In-Trade	-	-	-	-	-	-	-
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-	-
Employee Benefit Expenses	46.45	45.12	40.66	52.08	132.23	111.58	147.75
Finance Costs	0.54	0.64	0.50	0.61	1.69	1.30	2.03
Depreciation and Amortization Expenses	35.87	8.79	4.14	5.09	48.81	14.03	31.65
Other Expenses	62.94	61.11	55.54	42.29	179.60	98.00	124.92
Total Expenses	5,422.10	5,544.06	4,512.31	1,573.86	15,478.47	3,537.82	5,239.95
V Profit Before Exceptional and Extraordinary Items and Tax (III-IV)	685.10	665.13	523.08	315.38	1,873.30	749.90	1,093.77
VI Exceptional Items	-	-	-	-	-	-	-
VII Profit Before Extraordinary Items and Tax (V - VI)	685.10	665.13	523.08	315.38	1,873.30	749.90	1,093.77
VIII Extraordinary Items	-	-	-	-	-	-	-
IX Profit Before Tax (VII- VIII)	685.10	665.13	523.08	315.38	1,873.30	749.90	1,093.77
X Tax Expense:							
(1) Current Tax	12.08	23.52	19.54	0.93	55.14	43.38	49.95
(2) Deferred Tax	-	-	-	-	-	-	3.36
XI Profit / (Loss) For The Period From Continuing Operations (VII-VIII)	673.02	641.61	503.54	314.45	1,818.16	706.52	1,040.47
XII Profit / (Loss) For The Period From Discontinuing Operations	-	-	-	-	-	-	-
XIII Tax Expense of Discontinuing Operations	-	-	-	-	-	-	-
XIV Profit / (Loss) For The Period From Discontinuing Operations (After Tax) (XII-XIII)	-	-	-	-	-	-	-
XV Profit (Loss) For The Period (XI+XIV)	673.02	641.61	503.54	314.45	1,818.16	706.52	1,040.47
XVI Deatails of paid up Share Capital							
Paid up Share Capital	800.97	800.97	596.08	596.08	800.97	596.08	596.08
Face Value of Equity Share Capital(Per Share) (in Rs.)	10.00	10.00	10.00	10.00	10.00	10.00	10.00
XVII Earnings Per Equity Share (EPS)							
(i) Basic	8.40	8.01	8.45	5.28	22.70	11.85	17.46
(ii) Diluted							

Notes

- The Financial Results have been reviewed and recommended by the Audit Committee and thereafter approved by the Board of Directors in its meeting held on 5th February 2025.
- The figures for the Previous period/ Quarter & Nine month ended have been rearranged/re-grouped wherever necessary, to confirm with the figures for the current year/Quarter & Nine Month ended.
- The Financial results are prepared in accordance with the Accounting Standard ("AS") as prescribed under section 133 of the Companies Act, 2013 read with relevant rules.
- The entire operation of the Company relate to only one segment. Hence,Ind AS-108 is not applicable. Thus, no separate disclosure for segment reporting is made.

For & on behalf of the Board of Directors
Nirman Agri Genetics Limited

Pranav Kailas Bagal
Digitally signed by
Pranav Kailas Bagal
Date: 2025.02.05
13:25:32 +05'30'
Pranav Kailas Bagal
Managing Director
DIN - 08839908

Place - Nashik
Date - 05/02/2025